Repercusión de vortioxetina sobre la función sexual frente a otros antidepresivos / Impact of vortioxetine on sexual function compared to other antidepressants

Objetivo Analizar la repercusión del antidepresivo vortioxetina sobre la función sexual, frente a inhibidores selectivos de la recaptación de serotonina (ISRS) e inhibidores selectivos mixtos de la recaptación de serotonina y noradrenalina (IRSN o Duales) en pacientes con depresión. Material y métodos Estudio analítico, observacional, longitudinal y prospectivo en el que se incluyeron hombres y mujeres mayores de 18años con trastorno depresivo y actividad sexual en pareja, separándolos en dos grupos: 1)de estudio: inician tratamiento con vortioxetina; 2)control: mantienen tratamiento con ISRS o Duales. Se realizaron tres visitas: inclusión, seguimiento a las 4semanas y final 3meses desde la inclusión. El periodo total de seguimiento fue de 3meses. Resultados Se incluyeron 87 pacientes (edad media, 46,85años). Al final del estudio se hallaron diferencias significativas (DS) en el valor medio de la suma de las puntuaciones de los dominios evaluadores de la respuesta sexual del cuestionario de Función Sexual de la Mujer (FSM-2) entre el grupo de estudio y el de control (22,42±4,39 y 16,13±7,76, respectivamente), con menor riesgo de disfunción sexual en las mujeres tratadas con vortioxetina. También menor riesgo de disfunción sexual en estas mismas mujeres en los dominios de deseo, lubricación, orgasmo, frecuencia sexual y satisfacción sexual. Estas diferencias no se hallaron al evaluar la función sexual masculina. Conclusiones Las mujeres tratadas con vortioxetina presentaron mejor función sexual que las tratadas con ISRS o Duales y menor riesgo de disfunción sexual (AU)

Objective To analyze the impact of the antidepressant vortioxetine on sexual function, compared to selective serotonin reuptake inhibitors (SSRIs) and mixed selective serotonin and norepinephrine reuptake inhibitors (IRSN or Dual) in patients with depression. Material and methods Analytical, observational, longitudinal and prospective study, which included men and women over 18years of age, with depressive disorder and sexual activity with a partner, separating them into two groups: (i)study, starting treatment with vortioxetine; (2)control, maintaining treatment with SSRIs or Duals. Three visits were made: inclusion, follow-up at 4weeks and final 3months from inclusion. The total follow-up period was 3months. Results A total of 87 patients were included (mean age 46.85years). At the end of the study, significant differences (SD) were found in the mean value of the sum of the scores of the evaluative domains of the sexual response of the Women's Sexual Function Questionnaire (FSM-2) between the study group and the control (22.42±4.39 and 16.13±7.76, respectively), with a lower risk of sexual dysfunction in women treated with vortioxetine. Also, lower risk of sexual dysfunction in these same women in the domains of desire, lubrication, orgasm, sexual frequency and sexual satisfaction. These differences were not found when assessing male sexual function. Conclusions Women treated with vortioxetine presented better sexual function than those treated with SSRIs or Duals and a lower risk of sexual dysfunction (AU)

[Impact of vortioxetine on sexual function compared to other antidepressants]. / Repercusión de vortioxetina sobre la función sexual frente a otros antidepresivos.

OBJECTIVE: To analyze the impact of the antidepressant vortioxetine on sexual function, compared to selective serotonin reuptake inhibitors (SSRIs) and mixed selective serotonin and norepinephrine reuptake inhibitors (IRSN or Dual) in patients with depression. MATERIAL AND METHODS: Analytical, observational, longitudinal and prospective study, which included men and women over 18years of age, with depressive disorder and sexual activity with a partner, separating them into two groups: (i)study, starting treatment with vortioxetine; (2)control, maintaining treatment with SSRIs or Duals. Three visits were made: inclusion, follow-up at 4weeks and final 3months from inclusion. The total follow-up period was 3months. RESULTS: A total of 87 patients were included (mean age 46.85years). At the end of the study, significant differences (SD) were found in the mean value of the sum of the scores of the evaluative domains of the sexual response of the Women's Sexual Function Questionnaire (FSM-2) between the study group and the control (22.42±4.39 and 16.13±7.76, respectively), with a lower risk of sexual dysfunction in women treated with vortioxetine. Also, lower risk of sexual dysfunction in these same women in the domains of desire, lubrication, orgasm, sexual frequency and sexual satisfaction. These differences were not found when assessing male sexual function. CONCLUSIONS: Women treated with vortioxetine presented better sexual function than those treated with SSRIs or Duals and a lower risk of sexual dysfunction.

Análisis de la mortalidad neonatal en el Hospital Universitario La Fe de Valencia. Años 1971-2009 / Analysis of neonatal mortality in the University Hospital La Fe Valencia. Years 1971-2009

Introducción y objetivos: La mortalidad neonatal (MNN) es un indicador de calidad asistencial básico. El objetivo primario de este estudio ha sido el análisis de la evolución la MNN en el Hospital Universitario La Fe de Valencia (HULF), unidad de nivel IIIc, desde su inauguración en 1971 hasta el año 2009. Objetivos secundarios han sido la valoración de la tasa de prematuridad (PR) y bajo peso al nacimiento (BPN). Material y métodos: En este periodo se produjeron 308.989 nacimientos, en los que hubo 2.135 muertes neonatales. Resultados: La MNN muestra un descenso significativo (10,18‰ en 1971 vs 6,24‰ en 2009, p<0,001) Este descenso es aún más significativo para los neonatos con peso al nacimiento entre 500-999 gramos (923,1‰ en 1980 vs 238,1‰ en 2009, p<0,0001) y menor para los prematuros con edad gestacional inferior a 28 semanas (403,8‰ en 1993 vs 287,9‰ en 2009, p<0,01). La tasa de PR paso de 8,7% (1993) al 14% (2009) p<0,001. La tasa de BPN ascendió del 5,3% (1979) al 12.8% (2009), p<0,001. Los varones representan el 58,2% de las muertes neonatales y estas se producen en las primeras 24 h de vida en el 48,2%. La patología respiratoria representa el 36,3% de las muertes neonatales, las malformaciones severas el 31,5%, la patología neurológica el 14,6% y las infecciones el 7,9%. Conclusiones: A pesar del aumento de la PR y BPN se ha conseguido un descenso significativo de la MNN en el HULF(AU)

Background and objectives: Neonatal mortality (NM) is a reliable marker of quality clinical care. The primary objective of this study was to analyse evolution of NM in the Division of Neonatology (level IIIc according to the Spanish Classification) University Hospital La Fe Valencia (HULF) from the beginning of its activity in 1971 until 2009. Secondary objectives were the evaluation of prematurity rate (PR) and low birth weight rate (LBWR). Material and methods: There was a total of 308,989 births, with 2.135 neonatal deaths (ND), during the period studied. Results: NM has shown a significant decrease (10.18% in 1971 vs. 6.24% in 2009; P<0.01). This decrease was even more significant for neonates with birth weight between 500-999g (923.1% in 1980 vs. 238.1% in 2009; P<0.0001) and less for preterm with gestational age less than 28 weeks (403.8% in 1993 vs. 287.9% in 2009; P<0.01). The Prematurity rate increased from 8.7% (1993) to 14% (2009) (P<0.01), and LBWR increased from 5.3% (1979) to 12.8% (2009) (P<0.001). Males represent 58.2% of ND, and these occurred in the first day of life in 48.2% of the cases. Respiratory conditions represent 36.3% of ND, severe congenital malformations 31.5%, neurologic conditions 14.6%, and infections 7.9%. Conclusions: In spite of the increase in LBWR and PR, a significant descent of NM has been achieved in the HULF in the last decades(AU)

[Analysis of neonatal mortality in the University Hospital La Fe Valencia. Years 1971-2009]. / Análisis de la mortalidad neonatal en el Hospital Universitario La Fe de Valencia. Años 1971-2009.

BACKGROUND AND OBJECTIVES: Neonatal mortality (NM) is a reliable marker of quality clinical care. The primary objective of this study was to analyse evolution of NM in the Division of Neonatology (level IIIc according to the Spanish Classification) University Hospital La Fe Valencia (HULF) from the beginning of its activity in 1971 until 2009. Secondary objectives were the evaluation of prematurity rate (PR) and low birth weight rate (LBWR). MATERIAL AND METHODS: There was a total of 308,989 births, with 2.135 neonatal deaths (ND), during the period studied. RESULTS: NM has shown a significant decrease (10.18% in 1971 vs. 6.24% in 2009; P<.01). This decrease was even more significant for neonates with birth weight between 500-999g (923.1% in 1980 vs. 238.1% in 2009; P<.0001) and less for preterm with gestational age less than 28 weeks (403.8% in 1993 vs. 287.9% in 2009; P<.01). The Prematurity rate increased from 8.7% (1993) to 14% (2009) (P<.01), and LBWR increased from 5.3% (1979) to 12.8% (2009) (P<.001). Males represent 58.2% of ND, and these occurred in the first day of life in 48.2% of the cases. Respiratory conditions represent 36.3% of ND, severe congenital malformations 31.5%, neurologic conditions 14.6%, and infections 7.9%. CONCLUSIONS: In spite of the increase in LBWR and PR, a significant descent of NM has been achieved in the HULF in the last decades.

De la evidencia a la práctica clínica: manejo de la artrosis, II parte / No disponible

No disponible

Recomendaciones de buena práctica clínica en artrosis / No disponible

La artrosis constituye, como todos sabemos, una patología de alta prevalencia y de gran consumo de recursos sanitarios tanto en Atención Primaria como a nivel hospitalario. La presente Guía de “Recomendaciones de buena práctica clínica en artrosis” pretende dar a conocer conocimientos básicos en esta patología y alcanzar los objetivos idóneos tanto a nivel diagnóstico como terapéutico para plasmarlos en nuestra actuación clínica diaria. Dichas opciones han de estar basadas en pruebas avaladas de forma categórica y que se irán señalando dentro del contexto y desarrollo de esta Guía. Aún así, la artrosis presenta líneas abiertas de investigación en actuación sobre los factores de riesgo y sobre el uso de fármacos, que sólo desde la historia natural de la enfermedad y desde un seguimiento largo y de años, es decir desde Atención Primaria, se pueden ir desarrollando

Arthrosis is, as we all know, a disease having high prevalence that uses a large amount of health care resources in both Primary Health Care and in the Hospital. The present “Good clinical practice recommendations in arthrosis” Guide aims to provide basic knowledge in this disease and to help to reach the best objectives on the diagnostic and therapeutic levels to incorporate them into our daily clinical activity. These options should be based on tests supported categorically and that will be indicated within the context and development of this Guide. Even so, the lines of research for arthrosis regarding action on the risk factors and on the use of drugs that can only be developed from the natural history of the disease and from the long term follow-up over years, that is from Primary Health Care

Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain.

A cross-sectional survey was conducted to determine the current situation in Spain regarding diagnosis and care of patients with osteoporosis in the primary care setting. A total of 2,500 primary care physicians who were homogeneously grouped in autonomous communities throughout the country received a postal 30-item anonymous self-administered questionnaire. The questionnaire covered demographics and personal characteristics of the physicians, conditions in everyday consultation, and degree of knowledge with regard to risk factors, diagnosis, treatment, and follow-up of the disease. The overall response was 850 (34%). The mean age of physicians surveyed was 43 years (range 23-66 years). The percentage of physicians specialized in community and family medicine was 46.7%. In 55.2% of cases, years of practice ranged between 11 and 20, and 55.7% of physicians visited between 31 and 50 patients per day. Age and years of practice were not associated with daily number of visits. Only 4% of physicians stated that there were specific programs for osteoporosis implemented in their primary care center. Diagnostic complementary investigations that could be ordered included plain radiographs in 96.2% of cases and bone densitometry in 27.8%. Laboratory tests included serum hormones in 61.6% of cases, PTH in 50.2%, and bone alkaline phosphatase in 33.4%. The diagnosis of osteoporosis was made always personally in 25.2% of cases. Personal diagnosis and follow-up, as well as actions directed to detection of osteoporosis were significantly higher among physicians working in centers with specific programs for osteoporosis. With regard to knowledge about osteoporosis, the mean percentage of correct responses was 63%. The percentage of correct responses was inversely associated with age and years of practice, and positively associated with speciality of community and family medicine. Primary care providers are in a good position to assess risk factors and recommend prevention strategies, as well as to play an active role in the diagnosis, care, and follow-up of patients with osteoporosis. Practitioners of younger age and relatively few years of practice were those with more up-to-date information regarding the disease, and the existence of a specific program for osteoporosis seems to improve the management of this condition.